Sign in
Markets
Screener
Signals
Library
API
Help
Chat
Stories
AEON Biopharma Advances Migraine Treatments
Share
AB Science's Medical Breakthrough Webcas...
ABBio Innovates Antibody Development
ABIONYX Pharma Files 2023 Document
ACTICOR BIOTECH: Financial Report Postpo...
ADOCIA Files 2023 Registration Document
ANJESO Drug Insight and Market Forecast
Overview
API
AEON Biopharma progresses with ABP-450 migraine programs, secures $15M private placement for research and development endeavors.
Ask a question
How does the private placement of $15 million reflect investor confidence in AEON Biopharma's research and development efforts?
How might the FDA alignment impact the timeline for ABP-450's availability?
What potential benefits could ABP-450 bring to patients suffering from chronic migraines?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage